Swiss drugmaker Roche has launched a late-stage trial for trontinemab, a new Alzheimer's treatment designed to prevent symptoms by effectively crossing the blood-brain barrier. This initiative aims to overcome the limitations of current therapies and halt disease progression before cognitive decline begins.
in News